Company / Financials
Lexaria Bioscience Corp. Financials
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$464.3K
FY2025 · +105.2% YoY
Net Income
-$5.8M
FY2025 · +13.0% YoY
Profit Margin
-1248.3%
FY2025 · net income / revenue
ROE
-193.8%
FY2025 · return on equity
Total Assets
$4.2M
FY2025
Total Debt
-
FY2025
Equity
$3.0M
FY2025
ROA
-138.8%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$464.3K+105.2% YoYNet Income HistoryProfit after all expenses and taxes-$5.8M+13.0% YoYGross Profit HistoryRevenue minus cost of goods sold$459.5K+136.0% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$4.8K-84.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$5.8M+12.0% YoYSG&A Expense HistorySelling, general, and administrative expenses$3.9M+25.8% YoYR&D Expense HistoryResearch and development spending$2.4M-35.6% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense-EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.47+53.5% YoY